Department of Medicine, Renal Unit, University Hospital of Verona, Piazzale A. Stefani 1, 37126, Verona (VR), Italy.
Department of Neurosciences, Otolaryngology Section, University of Padova, Padova, Italy.
J Nephrol. 2022 Jan;35(1):223-232. doi: 10.1007/s40620-021-00983-6. Epub 2021 Feb 24.
Several studies have suggested that chronic kidney disease (CKD) may be associated with olfactory impairment. However, to date, the impact of renal replacement therapies has only been partly defined.
We tested the olfactory function of 235 participants [50 kidney transplant recipients (KT), 49 hemodialyzed patients (HD), 30 peritoneal dialysis patients (PD), 51 patients with CKD not on dialysis (ND-CKD) and 55 healthy subjects (HS)] by the Sniffin' Sticks test (Burghardt®, Wedel, Germany), including the sub-tests for the determination of odor threshold (T), odor discrimination (D), odor identification (I). Each subtest result was then summed up to a composite score, known as the TDI score. The Sino-Nasal Outcome Test-22 (SNOT22), Montreal Cognitive Assessment (MoCA) test and olfactory function Visual Analogue Scale (ofVAS) were also performed.
The mean TDI score was significantly lower (and consistent with hyposmia), in HD, PD and ND-CKD compared to HS and KT (ANOVA p < 0.001). Similar results were observed in the I and D tests, and with the T score, though with regard to the latter, only in PD and ND-CKD patients. Multiple comparisons among groups demonstrated no significant differences between KT and HS. After adjustments for confounding factors, a significant linear association was found between both urea (β - 0.03, p < 0.003) and eGFR (β 0.08, p < 0.001) with TDI score. No significant association was observed between the TDI score and the ofVAS score (p = 0.293).
Olfactory impairment affects a large number of CKD patients in the pre-dialysis phase as well as those on dialysis. Kidney transplantation may reverse this condition with a possible positive impact on the quality of life and social behaviors/relationships.
多项研究表明,慢性肾脏病(CKD)可能与嗅觉障碍有关。然而,迄今为止,肾替代治疗的影响仅部分得到定义。
我们通过嗅觉测试(Burghardt ® ,Wedel,德国)测试了 235 名参与者(50 名肾移植受者(KT),49 名血液透析患者(HD),30 名腹膜透析患者(PD),51 名未透析的 CKD 患者(ND-CKD)和 55 名健康受试者(HS))的嗅觉功能,包括确定嗅觉阈值(T)、嗅觉辨别(D)、嗅觉识别(I)的子测试。然后将每个子测试的结果相加得到一个综合分数,称为 TDI 分数。还进行了 Sino-Nasal Outcome Test-22(SNOT22)、蒙特利尔认知评估(MoCA)测试和嗅觉功能视觉模拟量表(ofVAS)。
与 HS 和 KT 相比,HD、PD 和 ND-CKD 的平均 TDI 评分明显较低(且与嗅觉减退一致)(ANOVA p < 0.001)。I 和 D 测试也观察到了类似的结果,而 T 测试则观察到了这一点,但仅在 PD 和 ND-CKD 患者中观察到了这一点。组间的多重比较显示 KT 和 HS 之间没有显著差异。在调整混杂因素后,发现 TDI 评分与尿素(β -0.03,p < 0.003)和 eGFR(β 0.08,p < 0.001)之间存在显著线性关联。TDI 评分与 ofVAS 评分之间无显著相关性(p = 0.293)。
嗅觉障碍影响大量处于透析前阶段的 CKD 患者以及接受透析的患者。肾移植可能会逆转这种情况,对生活质量和社会行为/关系产生可能的积极影响。